Literature DB >> 26191333

The role of EphB4 and IGF-IR expression in breast cancer cells.

Gena Huang1, Man Li2.   

Abstract

OBJECTIVE: to investigate the role of EphB4 and IGF-1R in the proliferation and migration of breast cancer.
METHODS: The relative mRNA levels of EphB4 were measured by RT-PCR. The proliferation of the cells was determined by MTT assay, and cells migration and invasive ability was analyzed using the scratch migration assay.
RESULTS: The expression of EphB4 in control group was significantly decreased when compared with IGF-I group (P<0.001). The expression of EphB4 in IGF-I+LY and LY group were lower than that of the control group (P<0.001).The cell proliferation and migration ability of the cells in IGF-I group increased significantly compared to the cells in the control group (P<0.001), while the cells in IGF-1+LY group and LY group showed a decreased proliferation and migration ability compared to the control group (P<0.001).
CONCLUSION: IGF-IR might be a upstream gene of EphB4. Besides, higher expression of EphB4 shows increased tumor proliferation and migration in breast cells. The study of EphB4 upstream gene and signaling pathway can provide more targeted anti-tumor point selection for targeted therapy.

Entities:  

Keywords:  EphB4; IGF-IR; breast cancer cell

Mesh:

Substances:

Year:  2015        PMID: 26191333      PMCID: PMC4503204     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  27 in total

1.  Cancer cells exploit the Eph-ephrin system to promote invasion and metastasis: tales of unwitting partners.

Authors:  Bingcheng Wang
Journal:  Sci Signal       Date:  2011-05-31       Impact factor: 8.192

2.  The EphB4 receptor promotes the growth of melanoma cells expressing the ephrin-B2 ligand.

Authors:  Nai-Ying Yang; Pablo Lopez-Bergami; James S Goydos; Dana Yip; Ameae M Walker; Elena B Pasquale; Iryna M Ethell
Journal:  Pigment Cell Melanoma Res       Date:  2010-07-23       Impact factor: 4.693

3.  Imatinib mesylate enhances the malignant behavior of human breast carcinoma cells.

Authors:  Germana Rappa; Fabio Anzanello; Aurelio Lorico
Journal:  Cancer Chemother Pharmacol       Date:  2010-07-02       Impact factor: 3.333

Review 4.  The Cain and Abl of epithelial-mesenchymal transition and transforming growth factor-β in mammary epithelial cells.

Authors:  Tressa M Allington; William P Schiemann
Journal:  Cells Tissues Organs       Date:  2010-11-03       Impact factor: 2.481

5.  Converging evidence for efficacy from parallel EphB4-targeted approaches in ovarian carcinoma.

Authors:  Whitney A Spannuth; Lingegowda S Mangala; Rebecca L Stone; Amy R Carroll; Masato Nishimura; Mian M K Shahzad; Sun-Joo Lee; Myrthala Moreno-Smith; Alpa M Nick; Ren Liu; Nicholas B Jennings; Yvonne G Lin; William M Merritt; Robert L Coleman; Pablo E Vivas-Mejia; Yue Zhou; Valery Krasnoperov; Gabriel Lopez-Berestein; Parkash S Gill; Anil K Sood
Journal:  Mol Cancer Ther       Date:  2010-08-03       Impact factor: 6.261

6.  Attenuation of ephrinB2 reverse signaling decreases vascularized area and preretinal vascular tuft formation in the murine model of oxygen-induced retinopathy.

Authors:  Alyssa C Taylor; Thomas A Mendel; Katelyn E Mason; Katherine E Degen; Paul A Yates; Shayn M Peirce
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-08-13       Impact factor: 4.799

7.  Expression of EphB4 in head and neck squamous cell carcinoma.

Authors:  Uttam K Sinha; Ajay Kundra; Pierluigi Scalia; Diane L Smith; Behdad Parsa; Rizwan Masood; Parkash S Gill
Journal:  Ear Nose Throat J       Date:  2003-11       Impact factor: 1.697

8.  EphrinB2-EphB4 signals regulate formation and maintenance of funnel-shaped valves in corneal lymphatic capillaries.

Authors:  Hideto Katsuta; Yoko Fukushima; Kazuichi Maruyama; Masanori Hirashima; Kohji Nishida; Shin-Ichi Nishikawa; Akiyoshi Uemura
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-06-12       Impact factor: 4.799

9.  Activation of the receptor protein tyrosine kinase EphB4 in endometrial hyperplasia and endometrial carcinoma.

Authors:  G Berclaz; E Karamitopoulou; L Mazzucchelli; V Rohrbach; E Dreher; A Ziemiecki; A-C Andres
Journal:  Ann Oncol       Date:  2003-02       Impact factor: 32.976

10.  EphB4 is overexpressed in gliomas and promotes the growth of glioma cells.

Authors:  Tao Chen; Xiaoyu Liu; Shanghui Yi; Jiannan Zhang; Jianwei Ge; Zhigang Liu
Journal:  Tumour Biol       Date:  2012-11-09
View more
  4 in total

1.  EPHB4 is a therapeutic target in AML and promotes leukemia cell survival via AKT.

Authors:  Akil A Merchant; Aparna Jorapur; Amy McManus; Ren Liu; Valery Krasnoperov; Parvesh Chaudhry; Mohan Singh; Lisa Harton; Mary Agajanian; Miriam Kim; Timothy J Triche; Brian J Druker; Jeffrey W Tyner; Parkash S Gill
Journal:  Blood Adv       Date:  2017-08-28

2.  Vandetanib drives growth arrest and promotes sensitivity to imatinib in chronic myeloid leukemia by targeting ephrin type-B receptor 4.

Authors:  Weina Ma; Man Zhu; Bo Wang; Zhengyan Gong; Xia Du; Tianfeng Yang; Xianpeng Shi; Bingling Dai; Yingzhuan Zhan; Dongdong Zhang; Yanhong Ji; Yang Wang; Song Li; Yanmin Zhang
Journal:  Mol Oncol       Date:  2022-06-27       Impact factor: 7.449

Review 3.  Natural Products for Chemoprevention of Breast Cancer.

Authors:  Eun-Yi Ko; Aree Moon
Journal:  J Cancer Prev       Date:  2015-12-30

Review 4.  Current Advances in Coptidis Rhizoma for Gastrointestinal and Other Cancers.

Authors:  Luying He; Zhangfeng Zhong; Man Chen; Qilian Liang; Yitao Wang; Wen Tan
Journal:  Front Pharmacol       Date:  2022-01-03       Impact factor: 5.988

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.